Latest news for PHarol SGPS (OTC:PHRZF) Stock

PHarol SGPS SA is a holding company that owns shares in companies operating in the telecommunication field.

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

AAVMY

ACNNF

AFTM

ALTERNATE HEALTH CORP ORD by Alternate Health Corp.

AHGIF

ALDS

AMLM

AMRK

APWC

AQMS

ARLP

AVCNF

AXVEF

AXXIY

BEEI

BEEN

BLEVF

BLUBF

BMSN

BNKPF

BOSC

CAMZF

CGOTF

CHBU

CNONF

COWI

CRPOF

CRXPF

CTABF

CTRA

CTST

CWYCY

DCTH

DLPN

DRRSF

DRWN

EGTYF

ELNOF

EPAZ

EVLO

EUROPEAN ELECTRIC METALS by European Electric Metals Inc.

EVXXF

FRONTERA ENERGY CORP ORD by Frontera Energy Corp

FECCF

FUTURE FARM TECHNOLOGIES by Future Farm Technologies Inc.

FFRMF

FISOF

FLOOF

GALKF

GASNF

GCAN

GETH

GLOP

GOHE

GTBP

GVDI

HGEN

HLLXF

ICNAF

IMMR

INDXF

INOH

IRBT

JAMN

JASN

KOIOS BEVERAGE CORP by Koios Beverage Corp.

KBEVF

KOSK

KSMRF

MGLDF

MITK

MJARF

MNGG

MOGU

MSNVF

MTLCF

MTVX

NBEV

NGXXF

NLBIF

NSCO

NTGR

NTSFF

NXGWF

OILCF

OZSC

PGHEF

PGOL

POAI

POTG

PPSI

PRGX

PVHO

Stocks That Hit 52-Week Lows On Monday

PHarol SGPS SA

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4310591-1&amp;h=595178996&amp;u=https%3A%2F%2Fwww.equinix.com%2F&amp;a=Equinix%2C+Inc.">Equinix, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>), the world's digital infrastructure company&#xAE;, today announced that it has issued an additional €1.15 billion in green bonds. This builds on more than <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4310591-1&amp;h=1997079284&amp;u=https%3A%2F%2Fwww.equinix.com%2Fnewsroom%2Fpress-releases%2F2024%2F09%2Fequinix-issues-more-than-750-million-in-green-bonds-to-drive-sustainability-initiatives&amp;a=%24750+million+offerings">$750 million offerings</a> in green bonds that Equinix completed in September this year. With these latest issuances, Equinix will have issued a total of approximately $6.9 billion of green bonds, making it a top 5 issuer of green bonds in the U.S. Equinix will utilize the green bonds to further its sustainability initiatives and enhance the operational efficiency of its global business.

EQIX

Equinix Expands Sustainability Initiatives With Additional €1.15 Billion In Green Bonds

Goldman Sachs analyst Tina Hou downgrades NIO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) from Neutral to Sell and lowers the price target from $4.8 to $3.9.

Downgrades

Price Target

Analyst Ratings

Goldman Sachs Downgrades NIO to Sell, Lowers Price Target to $3.9

WIIM

RGTI

Rigetti shares are trading higher after the company completed a $100 million at-the-market equity offering, with plans to use the proceeds for working capital, capital expenditures, and advancements in superconducting quantum computing technology.

STXS

Stereotaxis Genesis Robotic System Secures Regulatory Approval In China, Marking Key Milestone In Partnership With MicroPort EP For Commercial Launch Of Advanced Robotic And Electrophysiology Solutions

Kenneth M. Jacobs Becomes Senior Chairman of the Firm
Richard D. Parsons Honored for Board Service
Lazard, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) today announced that <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.lazard.com%2Four-people%2Fdan-schulman%2F&amp;esheet=54157314&amp;newsitemid=20241125060990&amp;lan=en-US&amp;anchor=Dan+Schulman&amp;index=1&amp;md5=9294548d22d082dcbbe72301bde1930a">Dan Schulman</a>, Board Member, has been appointed Lead Independent Director to succeed <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.lazard.com%2Four-people%2Frichard-d-parsons%2F&amp;esheet=54157314&amp;newsitemid=20241125060990&amp;lan=en-US&amp;anchor=Richard+D.+Parsons&amp;index=2&amp;md5=7551326cfaedc7f2d975c528ec35a23c">Richard D. Parsons</a>, who remains on the Board, and that <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.lazard.com%2Four-people%2Fpeter-r-orszag%2F&amp;esheet=54157314&amp;newsitemid=20241125060990&amp;lan=en-US&amp;anchor=Peter+R.+Orszag&amp;index=3&amp;md5=33bfe6ade736456635c0ba1bc89a1282">Peter R. Orszag</a>, Lazard CEO and Board Member, has been appointed Chairman of the Board, effective January 1, 2025.
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.lazard.com%2Four-people%2Fkenneth-jacobs%2F&amp;esheet=54157314&amp;newsitemid=20241125060990&amp;lan=en-US&amp;anchor=Kenneth+M.+Jacobs&amp;index=4&amp;md5=15c384676e8047d00a69bda405018059">Kenneth M. Jacobs</a>, Executive Chairman and Board Member, will become Senior Chairman of the Firm and Senior Advisor to the Board, and relinquish his board seat effective December 31, 2024. In his role as Senior Chairman, Mr. Jacobs will continue to advise many of the firm's most important clients and relationships globally.
These transitions represent a successful, multi-year succession planning process across Board and senior leadership at the firm.

Management

Lazard Appoints Peter R. Orszag As Chairman Of The Board; Kenneth M. Jacobs Becomes Senior Chairman Of The Firm

Targeting $150B U.S. And EMEA Markets While Addressing Underserved Communities Through BEAD Program

GRRR

Gorilla And BroadSat Partner To Revolutionize Digital Connectivity With Smart Cities And AI Cybersecurity Solutions

Meritage Homes Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTH#NYSE">MTH</a>, "Meritage" or the "Company"))), the fifth-largest homebuilder in the U.S., today announced that its Board of Directors has declared a two-for-one stock split of Meritage's common stock in the form of a stock dividend. Each stockholder of record at the close of business on December 31, 2024 will receive one additional share of common stock for each share of common stock held, payable after the close of market on January 2, 2025. Trading will begin on a split-adjusted basis on January 3, 2025.

Stock Split

Meritage Homes Announces 2-For-1 Stock Split; Trading Will Begin On A Split-Adjusted Basis On January 3, 2025

Eyenovia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) ("Eyenovia" or the "Company"), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that it has entered into a securities purchase agreement with a healthcare focused institutional investor for the purchase and sale of 12,081,785 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 24,163,570 shares of common stock in a registered direct offering at a combined offering price of $0.1076 per share and accompanying warrants. The warrants will have an exercise price of $0.1076 per share, will be exercisable commencing six months from the date of issuance and will expire five years from the initial exercise date. The closing of the offering is expected to take place on or about November 26, 2024, subject to the satisfaction of customary closing conditions.
The gross proceeds of the offering will be approximately $1.3 million before deducting placement agent fees and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, which may include the partial repayment of amounts outstanding under the Loan and Security Agreement with Avenue Capital Management II, L.P. and related entities, and, to the extent possible, advancement of the Company's next generation Optejet device, commercialization activities for Mydcombi and clobetasol propionate, and the exploration and pursuit of strategic alternatives.
Chardan is acting as sole placement agent for the offering.

Offerings

EYEN

Eyenovia, Inc. Announces Pricing Of $1.3M Registered Direct Offering

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and maintains $180 price target.

Reiteration

AXSM

HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $180 Price Target

Palantir Technologies Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) experienced a 3.25% increase in pre-market trading on Monday, as per <a href="https://pro.benzinga.com">Benzinga Pro</a>. This rise follows the company&#8217;s recent announcement of its transition&nbsp;from the NYSE to the&nbsp;Nasdaq, with trading set to begin on Nov. 26.
Palantir&#8217;s stock will continue under the ticker &#8220;PLTR.&#8221; The <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42014351/palantir-prepares-nasdaq-move-could-nasdaq-100-be-next">move to Nasdaq </a>is part of a broader trend, as the exchange has attracted 16 significant companies this year, including&nbsp;Science Applications International Corp&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NYSE">SAIC</a>) and&nbsp;Campbell Soup Company&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NYSE">CPB</a>). 
While Palantir has not confirmed any plans to join the Nasdaq-100, the potential inclusion could enhance its visibility and attract investor interest. Historically, companies switching to Nasdaq have often joined this prestigious index, which could lead to increased demand for Palantir shares. 
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42152684/musk-tweet-sparks-dogecoin-surge-fuels-speculation-on-x-payments?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Musk Tweet Sparks Dogecoin Surge, Fuels Speculation On X Payments</a>
Why It Matters: The transition of Palantir Technologies Inc. to the Nasdaq comes amid a significant surge in its stock value, which has increased by 288% year-to-date. This remarkable growth is partly attributed to the company&#8217;s strategic focus on artificial intelligence. 
Dan Ives has raised <a href="https://www.benzinga.com/news/global/24/11/42156160/palantir-price-target-raised-to-75-by-dan-ives-amid-288-ytd-surge-analyst-calls-2025-a-primetime-year-for-ai">Palantir&#8217;s price target</a> to $75, reflecting confidence in the AI software sector&#8217;s potential. Ives predicts that 2025 will be a pivotal year for AI implementation, further boosting the software sector&#8217;s growth. This optimistic outlook aligns with Palantir&#8217;s ongoing efforts to enhance its AI capabilities, positioning the company to capitalize on the anticipated AI revolution.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/11/42134031/markets-got-it-wrong-after-elections-prospects-of-tariffs-not-good-for-equities-vs-dollar-says-ex-goldman-sachs-analyst?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Markets Misread Trump Win, Says Ex-Goldman Sachs Analyst: &#8216;Prospects Of Tariffs Not Good For Equities&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Equities

Pre-Market Outlook

PLTR

SAIC

Palantir Surges In Monday Pre-Market As Top Tech Bull Raises Price Target To $75 Ahead Of Nasdaq Listing

Rigetti Completes $100M At-The-Market Equity Offering, Plans To Use Proceeds For Working Capital, Capital Expenditures, And Advancements In Superconducting Quantum Computing Technology

Chanson International Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHSN#NASDAQ">CHSN</a>) (the "Company" or "Chanson"), a provider of bakery, seasonal, and beverage products through its chain stores in China and the United States, today announces a collaboration with a leading hotel and restaurant management enterprise in Yili, Xinjiang, China, Xinjiang Hengtai Investment Co., Ltd. ("Xinjiang Hengtai") to expand its coffee brand, Soul ● Song, through a franchise operation model in Yili. This milestone marks significant progress in the development of Chanson's Soul ● Song brand, further deepening its market presence and extending its brand influence in the Xinjiang region.
In July 2024, the Company celebrated the grand opening of a Soul ● Song café in partnership with Xinjiang Hengtai at the scenic Nalati National Tourist Resort in Yili, Xinjiang, China. Soul ● Song's innovative "blend bean concept" highlights the art of blending, offering diverse flavors to suit every customer's unique taste. The café quickly became a must-visit destination within the resort, breaking the Company's single-day coffee-related sales record by achieving daily sales of RMB 30,000 on both August 8 and August 15, 2024. This marks Chanson's first attempt in adopting a franchise model, partnering with a distinguished local enterprise for mutual growth and success. Building on its growing influence in the Yili region, the Company plans to open five additional Soul ● Song cafés under the franchise model by 2025.

CHSN

Chanson International Holding Announces A Collaboration With Xinjiang Hengtai Investment Co., Ltd. To Expand Its Coffee Brand, Soul Song, Through A Franchise Operation Model In Yili

Highlights How Positive Data in AIM's Clinical Pipeline and Big Pharma Partnerships are Positioning the Company for Commercialization Opportunities in High-Value Indications Including Pancreatic Cancer
Warns Shareholders of Its Belief that the Activist Group and Its Nominees Have a Self-Interested Agenda and Could Put AIM's Clinical Progress at Risk
Urges Shareholders to Safeguard AIM by Voting "FOR" ALL Four of the Board's Incumbent Candidates and Discarding Any Proxy Materials from the Activist Group
Shareholders Can View and Download the Presentation <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Faimimmunotech.s3.us-west-1.amazonaws.com%2FAIM%2BInvestor%2BPresentation%2B%28November%2B2024%29.pdf&amp;esheet=54157417&amp;newsitemid=20241125176144&amp;lan=en-US&amp;anchor=Here&amp;index=1&amp;md5=aebd9987f2d8525d889b11917beb3e81">Here</a>
AIM ImmunoTech Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) ("AIM" or the "Company") today issued a <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Faimimmunotech.s3.us-west-1.amazonaws.com%2FAIM%2BInvestor%2BPresentation%2B%28November%2B2024%29.pdf&amp;esheet=54157417&amp;newsitemid=20241125176144&amp;lan=en-US&amp;anchor=presentation&amp;index=2&amp;md5=f3ad08194b4528269f1b5432d10f7266">presentation</a> in connection with its upcoming 2024 Annual Meeting of Stockholders the ("Annual Meeting"), presently scheduled for December 17, 2024.
Highlights of the presentation include the following:
<ul>
<li>AIM is executing on its strategy to create long-term value for patients and shareholders by driving clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space.</li>
<li>AIM's clinical pipeline has significant momentum and is laying the groundwork for commercialization opportunities by delivering exciting data across clinical trials, including in two ongoing studies with AstraZeneca and Merck. These commercialization opportunities are what can drive substantial value creation.</li>
<li>If elected, the Activist Group intends to seek over $5 million from AIM to pay for its previous takeover attempts and litigation against the Company that the Activist Group lost, in addition to any expenses incurred in connection with its solicitation for this year's Annual Meeting. The Activist Group disclosed that it does notintend to put this personal reimbursement to a shareholder vote.</li>
<li>Despite AIM's best attempts at a constructive settlement that would put two of the Activist Group's nominees on the Board, the Activist Group has continued to insist it receive upwards of $8 million to make all litigants whole in connection with certain litigation as part of any resolution – this represents more than 50% of AIM's current market capitalization.</li>
<li>The Activist Group has indicated it would likely appoint Robert Chioini as interim CEO while the Board runs a succession process should its nominees gain control of the Board. Mr. Chioini was fired as CEO of Rockwell Medical in 2018 because of his "sustained mismanagement" of the company and "blatant disregard for shareholder concerns," according to a Rockwell Medical spokesperson.1 Following his termination, Mr. Chioini "refuse[d] to accept the decision" and, without authorization, filed a Current Report on Form 8-K on the company's behalf "making various assertions regarding the five independent directors who voted in favor of Mr. Chioini's removal."2This behavior indicates, in our view, that Mr. Chioini is unfit to serve as a public company director – let alone CEO.</li>
</ul>

AIM ImmunoTech Issues Presentation Detailing Case For Re-Electing Current Directors To Oversee Continued Momentum And Drive Strategy To Create Long-Term Value For Patients And Shareholders; Warns Shareholders Of Its Belief That The Activist Group And Its Nominees Have A Self-Interested Agenda And Could Put AIM's Clinical Progress At Risk

Contracts

VUZI

Vuzix Announces Six-Figure Production Order For Customized Waveguides From A Defense Customer

Evercore ISI Group analyst David Motemaden reinstates Marsh &amp; McLennan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) with a Outperform and announces $242 price target.

Initiation

Evercore ISI Group Reinstates Outperform on Marsh & McLennan, Announces $242 Price Target

Diana Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DSX#NYSE">DSX</a>) reported quarterly sales of $57.49 million which missed the analyst consensus estimate of $68.00 million by 15.46 percent. This is a 7.37 percent decrease over sales of $62.06 million the same period last year.

Earnings

Earnings Misses

Diana Shipping Q3 Sales $57.49M Miss $68.00M Estimate

Upexi, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPXI#NASDAQ">UPXI</a>) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct-to-Consumer brand owner and innovator in aggregation, announces the Company has filed a complaint in the United States District Court for the District of Nevada to pursue the groups and individuals who orchestrated the manipulative and fraudulent activity in the shares round-up scheme related to Upexi's reverse stock split. Upexi anticipates that the court, through the discovery process, will enable the Company to determine who are the individuals owning the accounts and engaged in the manipulative trading transactions within those accounts in connection with and around the announcement and effective date of Upexi's reverse stock split. The Company and its legal team will pursue aggressively obtaining the relief that it seeks in the Complaint.
The Company previously announced the reverse stock split. Several weeks subsequent to the effective date, the financial institutions where the suspect trading took place requested 202,183 round-up shares, which represented more than a 19% dilution to our current shareholders and an increase of approximately 40 times the number of individual shareholders owning the Company's common stock immediately prior to the reverse split. The foregoing activity appears to have occurred during the three-day trading period between the announcement of the reverse split and its effective date.

UPXI

Upexi Files Litigation In Nevada As First Step In Determining Manipulation Of Fractional Share Roundups During Reverse Stock Split; Says 'Co And Its Legal Team Will Pursue Aggressively Obtaining The Relief That It Seeks In The Complaint'

SPAI

Safe Pro's Airborne Response Secures 2025 Drone Inspection Contract For Telecom Towers In South Florida, Highlighting Growing Q4 Drone Services Revenue From Hurricane Milton Recovery Efforts; Financial Terms Not Disclosed

In the current session, the stock is trading at $90.38, after a 0.21% increase. Over the past month, Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) stock increased by 2.40%, and in the past year, by 21.04%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1732540506_0.png" alt="Past Year Chart" />

<h3>Gilead Sciences P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of 94.75 in the Biotechnology industry, Gilead Sciences Inc. has a higher P/E ratio of 1002.11. Shareholders might be inclined to think that Gilead Sciences Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1732540506_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

GILD

Price Over Earnings Overview: Gilead Sciences

Abits Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABTS#NASDAQ">ABTS</a>), a U.S.-based digital data center operator specializing in Bitcoin self-mining operations, today announced it has signed agreements with Bitmain to purchase an additional 400 units of Antminer T21 for delivery by early December. Following the return of previously announced 500 units of S19 XP, the company has strategically shifted to the more advanced T21 miners. This purchase will increase the total mining fleet at its Tennessee site to 2,375 units, comprising:
<ul>
<li>1,370 units of Antminer S19 XP Hydro (featuring hydro-cooling technology)</li>
<li>305 units of Antminer S19J Pro</li>
<li>700 units of Antminer T21</li>
</ul>
The T21 delivers a hash rate of 190 TH/s per unit with power efficiency of 19J/T. These new machines come with a one-year manufacturer warranty. The additional 400 units will boost the total hash power by approximately 76 PH/s to over 500 PH/s.

ABTS

ABITS GROUP Acquires Additional 400 Units Of Antminer T21 For Delivery By Early December; Purchase Will Increase The Total Mining Fleet At Its Tennessee Site To 2,375 Units

PHarol SGPS

Comments

PHarol SGPS

News

Latest news for PHarol SGPS (OTC:PHRZF) Stock

Monday, December 02, 2019

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga